Therapeutic Choices in Hepatology, 2025

Nov 08 2025
Convention Center: Room 146C, Level 1
11:00 AM - 12:30 PM

World Class Speakers

Jordan J Feld, MD, MPH, FAASLD
Presenter

Jordan J Feld, MD, MPH, FAASLD

Toronto General Hospital
Aparna Goel, MD
Presenter

Aparna Goel, MD

Stanford University Medical Center
Jonathan G Stine, MD, MSc
Presenter

Jonathan G Stine, MD, MSc

Pennsylvania State University
Sonal Kumar, MD
Moderator

Sonal Kumar, MD

Description

In this case-based program, presenters provide updates on key topics in general hepatology including: (1) steatotic liver disease, with emphasis on the treatment of MASH and considerations surrounding diagnosis and management of MetALD; (2) hepatitis B management based on the AASLD 2025 guidelines; and (3) primary sclerosing cholangitis, particularly addressing screening, use of pharmacotherapy, and drug development. Cases are used to give clinicians a real-world approach to management of these common liver diseases.

Journey Maps

Presentations

11:00 AM - 11:30 AM
Nov 08 2025
San Diego, CA

Hepatitis B Management With the New American Association for the Study of Liver Diseases Guidelines

Jordan J Feld, MD, MPH, FAASLD, Presenter
Hepatitis
MASLD
11:30 AM - 12:00 PM
Nov 08 2025
San Diego, CA

Management of Patients With Primary Sclerosing Cholangitis

Aparna Goel, MD, Presenter
Hepatitis
MASLD
12:00 PM - 12:30 PM
Nov 08 2025
San Diego, CA

Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and MetALD

Jonathan G Stine, MD, MSc, Presenter
Hepatitis
MASLD

Objectives

  • Discuss US Food and Drug Administration approved drugs with established or potential efficacy in MASH (resmetirom, incretin mimetics, and vitamin E), indications for use, and how to choose which agent to use in various clinical scenarios.
  • Review how to diagnose MetALD in clinical practice, selection of optimal treatments for both the metabolic dysfunction-associated and alcohol-associated components of the disease, and monitoring for response.
  • Detail key changes to the updated AASLD clinical guidelines for HBV management, including indications for treatment and liver cancer screening.
  • Describe the monitoring and management of patients with primary sclerosing cholangitis with currently available tools and potential drug development for this condition.
Chair

Vincent Chen, MD

University of Michigan Medical Center